Mesoblast
FDA defies advisory panel recommendation, rejecting Mesoblast’s Ryoncil in paediatric steroid-refractory acute graft versus host disease
October 5, 2020Sales and Marketing FDA, Mesoblast, Ryoncil
The FDA has issued a surprising rejection of Mesoblast’s Ryoncil (remestemcel-L) as a treatment for paediatric steroid-refractory acute graft versus …
FDA panel votes 9-1 in favour of approval for Mesoblast’s Ryoncil in paediatric steroid-refractory acute graft versus host disease
August 14, 2020Medical Communications, Sales and Marketing FDA, Mesoblast, Ryoncil, pharma
It’s good news for Mesoblast as an expert FDA panel gave a glowing recommendation for the approval in the US …
Experimental stem cell treatment shows promise in rheumatoid arthritis
August 10, 2016Research and Development Mesoblast, rheumatoid arthritis, stem cell treatment
Mesoblast has announced results from a Phase II clinical trial evaluating MPC-300-IV in patients with biologic refractory rheumatoid arthritis (RA) …
Teva returns rights to heart cell therapy to Mesoblast
June 16, 2016Research and Development, Sales and Marketing Mesoblast, Teva, chronic heart failure, phase III
Israeli drugmaker Teva (NYSE: TEVA) has returned full rights to a drug for heart condition in late stage trials to …
Lonza signs regenerative medicine deal with Mesoblast
September 27, 2011Manufacturing and Production Lonza, Mesoblast, pharma manufacturing news
Lonza has entered into a strategic-level alliance with Mesoblast, a specialist in regenerative medicines, which could see the construction of …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
